Analyst Price Targets — LGND
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 2:43 pm | Joseph Pantginis | H.C. Wainwright | $243.00 | $231.11 | TheFly | Ligand price target raised to $243 from $239 at H.C. Wainwright |
| February 24, 2026 4:31 pm | Joseph Pantginis | H.C. Wainwright | $239.00 | $190.86 | TheFly | Ligand price target raised to $239 from $231 at H.C. Wainwright |
| December 10, 2025 12:09 pm | — | Stifel Nicolaus | $230.00 | $185.83 | TheFly | Ligand price target raised to $230 from $220 at Stifel |
| December 10, 2025 11:54 am | Trevor Allred | Oppenheimer | $275.00 | $185.83 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Ligand Pharma (LGND) |
| November 6, 2025 8:07 pm | Annabel Samimy | Stifel Nicolaus | $220.00 | $208.22 | StreetInsider | Ligand Pharma (LGND) PT Raised to $220 at Stifel |
| November 6, 2025 5:32 pm | — | H.C. Wainwright | $231.00 | $204.50 | TheFly | Ligand price target raised to $231 from $206 at H.C. Wainwright |
| November 3, 2025 12:37 pm | Leland Gershell | Oppenheimer | $250.00 | $192.97 | TheFly | Ligand price target raised to $250 from $190 at Oppenheimer |
| September 3, 2025 11:37 am | Leland Gershell | Oppenheimer | $190.00 | $165.76 | TheFly | Ligand price target raised to $190 from $167 at Oppenheimer |
| August 28, 2025 2:34 pm | — | H.C. Wainwright | $206.00 | $158.93 | TheFly | Ligand price target raised to $206 from $157 at H.C. Wainwright |
| February 28, 2025 1:32 pm | — | UBS | $155.00 | $122.23 | TheFly | Ligand price target raised to $155 from $143 at RBC Capital |
Latest News for LGND
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received approval from the U.S. Food and Drug…
Olema Pharmaceuticals (NASDAQ: OLMA - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership. Earnings and Valuation This table compares Olema Pharmaceuticals
Aberdeen Group plc cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 37.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 119,309 shares of the biotechnology company's stock after selling 70,439 shares during the period. Aberdeen Group plc
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among analysts
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) Director John Kozarich sold 467 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $202.23, for a total value of $94,441.41. Following the transaction, the director directly owned 42,253 shares in the company, valued at
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LGND.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.